CroíValve announced today that it received new funding from Horizon Europe’s European Innovation Council (EIC) Accelerator ...

The results suggest minimal health status benefits once TR has dropped by three grades, but further research is needed.

Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health Canada's approval for the treatment of tricuspid regurgitation (TR ...

CroíValve, a pioneering medical device company innovating a better way to help more patients suffering from Tricuspid ...

Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health Canada's approval for the treatment of tricuspid regurgitation (TR). The ...

It works in tandem with the native tricuspid valve to restore valve function while leaving the patient’s right heart and native valve apparatus untouched through an innovative anchoring mechanism.

Catheter ablation beat weight loss and antiarrhythmic drugs for reducing recurrent atrial fibrillation in patients with ...

Introduction Trivial tricuspid regurgitation (TR) is a common echocardiographic finding in healthy individuals. 1 However, significant TR (grade ≥2) has been shown to be associated with poor prognosis ...

The agency’s decision supports broader access to a minimally invasive treatment for patients with severe tricuspid ...

The overall evidence for the procedure is “insufficient” at present, but good enough to allow coverage, the agency says.